We’re excited to announce that our book, Urology: The Last Review 2026, is officially out!📣
It’s already available on our mobile app 📱
We also sent it to print today, with shipping expected to start June 10th.📯
Next post ➡️
Urology News reviewed our book “Urology: The Last Review 2026” calling it “unique” and “excellent value for money” 🤩
Read their review here 👉 https://t.co/fQf4ajQPrY
Buy your copy here https://t.co/3Cradb3OpO
Good luck to everyone getting ready for FEBU in November!
Got 5 minutes? Grab a cuppa and catch up on the latest in the field. ☕️
The new Urology News is live! From the science of Potassium citrate to essential advice for those in Core Surgical Training, there’s something for everyone.
Read Sep/Oct issue:https://t.co/IOBMCJvOxQ
Our new Words of Wisdom is out in @EUplatinum !
This year, while revising the prostate cancer chapter of Urology: The Last Review with @JGomezRivas, we ran into a few questions about the use of DRE in the EAU prostate cancer guidelines
Read it here 👉 https://t.co/BwwBJq9qv8
Long live DRE, die DRE ☝️
DRE may be dying as a screening test, but it is far from dead. The latest evidence supports removing DRE from routine screening in asymptomatic men, yet it still retains an important role in clinical staging until imaging fully replaces it
https://t.co/CvHkYpEzoC
Hello! 👋
We are pleased to share our new flowchart on urothelial bladder cancer, from diagnosis to the treatment of metastatic disease (2026 update).
It is freely available on our website: https://t.co/J2ExAnFzVY
Many thanks to @BenjaminPradere for reviewing it! 🙏
Enjoy!
✏️
Our 2026 Uro-Oncology Flowcharts are already available free of charge on our website. (https://t.co/J2ExAnFzVY)
Explore our Prostate Cancer Flowchart for a clear and practical overview of diagnosis and management pathways. Thank you, @JGomezRivas, for this great collaboration!
They're here! Shipments start next week (ahead of schedule! 🤩).
Pre-orders go out 1st with a tracking link per email. We ask for your patience as we go through the waiting list.
If you haven't yet, get your copy here 👉 https://t.co/BAtwdrnkiA
Good luck for FEBU! 💪
Our book Urology Unboxed was recently reviewed by Fatima Kayali from @Uro_News
We are truly delighted to hear that you consider the book “an excellent companion for current and aspiring urology residents.” Thank you so much!🙏
🔗https://t.co/w0r9qW4vDo
📘https://t.co/0hX61WclcM
We’re excited to announce that our book, Urology: The Last Review 2026, is officially out!📣
It’s already available on our mobile app 📱
We also sent it to print today, with shipping expected to start June 10th.📯
Next post ➡️
A huge thank you to all the reviewers for going the extra mile and making it possible to review the entire book within just two months of the EAU Guidelines 2026 release!
It is always an honour and a pleasure working with all of you!🌟
🩻Contrast-induced AKI:
one of the biggest myths still shaping clinical decisions
For decades we were taught:
👉 “Contrast damages the kidneys”
👉 “Avoid CT with contrast in CKD”
👉 “Hydrate, protect, delay imaging if needed”
But what if… most of this is wrong?🤔
->The uncomfortable reality
Modern evidence shows:
👉 Low-osmolar contrast rarely causes true nephrotoxicity
👉 Even in CKD, AKI, and ICU patients
👉 The risk is often overestimated—or nonexistent
So where did the fear come from?
📍 1950s high-osmolar contrast (actually toxic)
📍 Poorly controlled observational studies
📍 “Creatinine rise = contrast injury” assumption
👉 Correlation became causation
👉 And the dogma stayed
⚠️What recent data tells us
✔ No difference in AKI rates with vs without contrast
✔ No benefit from bicarbonate, NAC, or aggressive hydration
✔ Even ICU and AKI patients show no worsening outcomes
->Translation to real life
👉 The patient was going to develop AKI anyway...Not because of contrast!!
->The real problem: “Renalism”
👉 Avoiding necessary imaging
👉 Delaying diagnosis
👉 Choosing inferior tests
And that leads to:
❌ Missed PE
❌ Delayed sepsis source control
❌ Worse outcomes
->Clinical mindset shift
Instead of asking:
👉 “Will contrast harm the kidneys?”
We should ask:
👉 “Will NOT doing the scan harm the patient?”
->Who still deserves caution?
✔ eGFR <30
✔ Severe hemodynamic instability
✔ Multiple nephrotoxins
Even then:
👉 Optimize volume
👉 Minimize dose
👉 Don’t delay critical imaging
🤓Bottom line
✔ Contrast nephrotoxicity exists… but is rare
✔ The fear is bigger than the risk
✔ The harm of NOT imaging is often greater
In critical care
👉 We don’t treat creatinine
👉 We treat patients
And sometimes…
👉 The most dangerous thing is NOT the contrast
👉 It’s hesitation.
📃Reference
Florens N, Demiselle J.
Kidney360 7: 445–449, 2026. doi: https://t.co/CWzi7WC9Wx
Another UROfact for the week!
Phosphodiesterase type 5 inhibitors include: sildenafil, tadalafil, vardenafil, and avanafIl.
Sources: https://t.co/rKq2TjW6k9 and https://t.co/6vv2z9ZAvP
Thank you for the overwhelming support!
We are excited to begin work on the new edition!
If you need access to the content of the last review 25, it is still available in our App.
Finally, it’s here! 🎉
The 2025 edition is now ready to order 👉https://t.co/2ySfdAe035
Thrilled to welcome @amorgado4 and @andrea_cocci to our reviewers’ board.
A big thank you to all our reviewers for their dedication in bringing this new edition to life! 📚✨
Another 30 cases are live in the app, bringing the total to 60! 🤩
Whether you are new to urology, or resident preparing for your board exam, these cases are a great way to test yourself.
“Urology in Practice” is a unique digital book including imaging.
https://t.co/qgINSzxVye